"Item Id","Item URI","Dublin Core:Title","Dublin Core:Subject","Dublin Core:Description","Dublin Core:Creator","Dublin Core:Source","Dublin Core:Publisher","Dublin Core:Date","Dublin Core:Contributor","Dublin Core:Rights","Dublin Core:Relation","Dublin Core:Format","Dublin Core:Language","Dublin Core:Type","Dublin Core:Identifier","Dublin Core:Coverage","Item Type Metadata:Bibliography","Item Type Metadata:Biographical Text","Item Type Metadata:Occupation","Item Type Metadata:Death Date","Item Type Metadata:Birthplace","Item Type Metadata:Text","Item Type Metadata:Player","Item Type Metadata:Access","Item Type Metadata:Alternate URL","Item Type Metadata:Citation","Item Type Metadata:Accessibility","Item Type Metadata:Abstract","Item Type Metadata:Read Online","Item Type Metadata:Additional Exercise","Item Type Metadata:Email Body","Item Type Metadata:Interviewer","Item Type Metadata:Interviewee","Item Type Metadata:Location","Item Type Metadata:Transcription","Item Type Metadata:Local URL","Item Type Metadata:Original Format","Item Type Metadata:Physical Dimensions","Item Type Metadata:Duration","Item Type Metadata:Compression","Item Type Metadata:Producer","Item Type Metadata:Director","Item Type Metadata:Bit Rate/Frequency","Item Type Metadata:Time Summary","Item Type Metadata:Birth Date","Item Type Metadata:Subject Line","Item Type Metadata:From","Item Type Metadata:To","Item Type Metadata:CC","Item Type Metadata:BCC","Item Type Metadata:Number of Attachments","Item Type Metadata:Standards","Item Type Metadata:Objectives","Item Type Metadata:Materials","Item Type Metadata:Lesson Plan Text","Item Type Metadata:URL","Item Type Metadata:Event Type","Item Type Metadata:Participants","PDF Text:Text",tags,file,itemType,collection,public,featured
1738,https://repository.netecweb.org/items/show/1738,"COVID-19 Guidelines: Special Considerations in Children","Treatment & Care","NIH Guidelines
Key considerations:
- SARS-CoV-2 infection is generally milder in children than in adults, and a substantial proportion of children with the infection are asymptomatic.
- Most nonhospitalized children with COVID-19 will not require any specific therapy.
- Observational studies describe associations between severe COVID-19 and the presence of ≥1 comorbid conditions, including cardiac disease, neurologic disorders, prematurity (in young infants), diabetes, obesity (particularly severe obesity), chronic lung disease, feeding tube dependence, and immunocompromised status. Age (<1 year and 10–14 years) and non-White race/ethnicity are also associated with severe disease.
- Most children hospitalized for severe COVID-19 have not been fully vaccinated or are not eligible for COVID-19 vaccination.
- Data on the pathogenesis and clinical spectrum of SARS-CoV-2 infection are more limited for children than for adults.
- Vertical transmission of SARS-CoV-2 appears to be rare, but suspected or probable cases of vertical transmission have been described.
- A small subset of children and young adults with SARS-CoV-2 infection may develop multisystem inflammatory syndrome in children (MIS-C). Many patients with MIS-C require intensive care management. The majority of children with MIS-C do not have underlying comorbid conditions.
- Data on the prevalence of post-COVID conditions in children are limited but suggest that younger children may have fewer persistent symptoms than older children and adults.
",NIH,,,2022-08-08,"2022-07 by Andi, Special Populations Treatment & Care group (suggested to replace 931)
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - note ""constantly updated""",,,,,,,2024-12-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/special-considerations-in-children/,,,,"Children,COVID-19,Example,Pediatrics,R-SP,Treatment and Care",,Hyperlink,Discover,1,0
1633,https://repository.netecweb.org/items/show/1633,"NETEC COVID-19 Webinar Series (10/11/21): Pediatric Surge Responses and Crisis Standards of Care","Treatment & Care","Join us Monday, October 11th, at 1pm EDT / 12pm CDT for the next NETEC COVID-19 Webinar Series presentation, Pediatric Surge Responses and Crisis Standards of Care. Join our presenters as they discuss the impact of the pediatric surge during the COVID-19 pandemic. Topics will include pediatric crisis standards of care planning, concerns, and surge strategy to preserve pediatric systems of care. Questions from the audience will be welcome during the webinar.
Webinar slides attached.",NETEC,,,2021-10-11,"2022-07 by Kari, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group (3 yr) C&C",,,,,"Webinar only",,2026-12-31,,,,,,,"
",,,,,,,,,,,,,,,,"Monday, October 11, 2021 | 1:00 PM EST",,,,,,,,,,,,,,,,,https://youtu.be/dmwuduZWNiQ,"Webinar, watch at link below.",,,"2019-nCoV,Children,Contingency and crisis capacities,Coronavirus,COVID-19,Critical Care,Epidemic,Pandemic,Pediatrics,R-SP,Surge,Treatment and Care","https://repository.netecweb.org/files/original/eb5c3d1f2ed416fd049148aa0160b701.png,https://repository.netecweb.org/files/original/4c59097afdf59894786edd2c616bc034.pdf",Webinar,"Contingency and Crisis Capacities",1,0
1629,https://repository.netecweb.org/items/show/1629,"Pediatric COVID-19 Resources","Treatment & Care","This page contains links to: Pediatric COVID-19 JIT Resources, Clinical Pathways and Guidance, and Crisis Standards of Care.","National Pediatric Disaster Coalition",,,2021,"2022-07 by Kari, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - note ""Constantly updated Excellent resource""",,Y,,,,,2024-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.npdcoalition.org/resources/,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Example,Just in Time training (JIT),Pediatrics,R-SP",https://repository.netecweb.org/files/original/53ccd7128a832e51075e02372ce5913f.png,Hyperlink,Develop,1,0
1627,https://repository.netecweb.org/items/show/1627,"Crisis Standards of Care Resources","Treatment & Care","A site including several resources for consideration in your crisis standards of care planning, and links to recent Crisis Standards of Care Open discussions hosted by the Eastern Great Lakes Pediatric Consortium for Disaster Response and WRAP-EM.","Western Regional Alliance for Pediatric Emergency Management (WRAP-EM)",,,2021,"2022-07 by Kari, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - note ""Constantly updated Excellent resource""",,,,,,,2024-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://wrap-em.org/,,,,"Children,Crisis Standards of Care,Example,Pediatrics,R-SP,Standard of Care,Treatment and Care",https://repository.netecweb.org/files/original/3dac18a07e51233294db7e37cd306c75.png,Hyperlink,Develop,1,0
1624,https://repository.netecweb.org/items/show/1624,"Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding","Treatment & Care","Multisystem inflammatory syndrome in children (MIS-C) is a severe clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that remains poorly understood. ","Peart Akindele N, Kouo T, Karaba AH, Gordon O, Fenstermacher KZJ, Beaudry J, Rubens JH, Atik CC, Zhou W, Ji H, Tao X, Vaidya D, Mostafa H, Caturegli P, Blair PW, Sauer L, Cox AL, Persaud D.",,,2021-08-16,"2022-07 by Amyna, Special Populations Treatment & Care group",,,,,Publication,,2024-07-31,,,,,,,,,,"Peart Akindele, N., T. Kouo, A. H. Karaba, O. Gordon, K. Z. J. Fenstermacher, J. Beaudry, J. H. Rubens, C. C. Atik, W. Zhou, H. Ji, X. Tao, D. Vaidya, H. Mostafa, P. Caturegli, P. W. Blair, L. Sauer, A. L. Cox, and D. Persaud. 2021. ""Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding."" The Journal of infectious diseases 224 (4):606-15.
","Free online on journal site and Pub Med Central","
Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that remains poorly understood.
Methods: Hospitalized children <18 years of age with suspected coronavirus disease 2019 (COVID-19) (N = 53) were recruited into a prospective cohort study; 32 had confirmed COVID-19, with 16 meeting the US Centers for Disease Control criteria for MIS-C. Differences in nasopharyngeal viral ribonucleic acid (RNA) levels, SARS-CoV-2 seropositivity, and cytokine/chemokine profiles were examined, including after adjustments for age and sex.
Results: The median ages for those with and without MIS-C were 8.7 years (interquartile range [IQR], 5.5-13.9) and 2.2 years (IQR, 1.1-10.5), respectively (P = .18), and nasopharyngeal levels of SARS-CoV-2 RNA did not differ significantly between the 2 groups (median 63 848.25 copies/mL versus 307.1 copies/mL, P = .66); 75% of those with MIS-C were antibody positive compared with 44% without (P = .026). Levels of 14 of 37 cytokines/chemokines (interleukin [IL]-1RA, IL-2RA, IL-6, IL-8, tumor necrosis factor-α, IL-10, IL-15, IL-18, monocyte chemoattractant protein [MCP]-1, IP-10, macrophage-inflammatory protein [MIP]-1α, MCP-2, MIP-1β, eotaxin) were significantly higher in children with MIS-C compared to those without, irrespective of age or sex (false discovery rate <0.05; P < .05).
Conclusions: The distinct pattern of heightened cytokine/chemokine dysregulation observed with MIS-C, compared with acute COVID-19, occurs across the pediatric age spectrum and with similar levels of nasopharyngeal SARS-CoV-2 RNA.
Keywords: COVID-19; MIS-C; SARS-CoV-2; coronavirus; viral RNA.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
",https://academic.oup.com/jid/article/224/4/606/6283764,,,,,,,,,,,,,,,,,,,,,,,,,,,https://pubmed.ncbi.nlm.nih.gov/34398245/,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Pediatrics,R-Res&Pub,R-SP,SARS-CoV-2,Treatment and Care",,Publication,Discover,1,0
1578,https://repository.netecweb.org/items/show/1578,"Treatment of Multisystem Inflammatory Syndrome in Children","Treatment & Care","Evidence is urgently needed to support treatment decisions for children with multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2.","the BATS Consortium","McArdle, Andrew J., Ortensia Vito, Harsita Patel, Eleanor G. Seaby, Priyen Shah, Clare Wilson, Claire Broderick, Ruud Nijman, Adriana H. Tremoulet, Daniel Munblit, Rolando Ulloa-Gutierrez, Michael J. Carter, Tisham De, Clive Hoggart, Elizabeth Whittaker, Jethro A. Herberg, Myrsini Kaforou, Aubrey J. Cunnington, and Michael Levin.",,2021-06-16,"2022-09-27 - general asset review - Treatment & Care group (to archive)
2022-07 by Amyna, Special Populations Treatment & Care group (said 2 years - in SPORSA went with SP)",,Y,,,Publication,,2024-07,,,,,,,,,,"McArdle, Andrew J., Ortensia Vito, Harsita Patel, Eleanor G. Seaby, Priyen Shah, Clare Wilson, Claire Broderick, Ruud Nijman, Adriana H. Tremoulet, Daniel Munblit, Rolando Ulloa-Gutierrez, Michael J. Carter, Tisham De, Clive Hoggart, Elizabeth Whittaker, Jethro A. Herberg, Myrsini Kaforou, Aubrey J. Cunnington, and Michael Levin. 2021. ""Treatment of Multisystem Inflammatory Syndrome in Children."" New England Journal of Medicine.
","Free online on NEJM.","Background
Evidence is urgently needed to support treatment decisions for children with multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2.
Methods
We performed an international observational cohort study of clinical and outcome data regarding suspected MIS-C that had been uploaded by physicians onto a Web-based database. We used inverse-probability weighting and generalized linear models to evaluate intravenous immune globulin (IVIG) as a reference, as compared with IVIG plus glucocorticoids and glucocorticoids alone. There were two primary outcomes: the first was a composite of inotropic support or mechanical ventilation by day 2 or later or death; the second was a reduction in disease severity on an ordinal scale by day 2. Secondary outcomes included treatment escalation and the time until a reduction in organ failure and inflammation.
Results
Data were available regarding the course of treatment for 614 children from 32 countries from June 2020 through February 2021; 490 met the World Health Organization criteria for MIS-C. Of the 614 children with suspected MIS-C, 246 received primary treatment with IVIG alone, 208 with IVIG plus glucocorticoids, and 99 with glucocorticoids alone; 22 children received other treatment combinations, including biologic agents, and 39 received no immunomodulatory therapy. Receipt of inotropic or ventilatory support or death occurred in 56 patients who received IVIG plus glucocorticoids (adjusted odds ratio for the comparison with IVIG alone, 0.77; 95% confidence interval [CI], 0.33 to 1.82) and in 17 patients who received glucocorticoids alone (adjusted odds ratio, 0.54; 95% CI, 0.22 to 1.33). The adjusted odds ratios for a reduction in disease severity were similar in the two groups, as compared with IVIG alone (0.90 for IVIG plus glucocorticoids and 0.93 for glucocorticoids alone). The time until a reduction in disease severity was similar in the three groups.
Conclusions
We found no evidence that recovery from MIS-C differed after primary treatment with IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone, although significant differences may emerge as more data accrue. (Funded by the European Union’s Horizon 2020 Program and others; BATS ISRCTN number, ISRCTN69546370. opens in new tab.)
",https://www.nejm.org/doi/full/10.1056/NEJMoa2102968,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.nejm.org/doi/full/10.1056/NEJMoa2102968,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Example,Pediatrics,R-Res&Pub,R-SP,Treatment and Care",,Publication,Discover,1,0
1576,https://repository.netecweb.org/items/show/1576,"Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes","Treatment & Care","The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.","the Overcoming COVID-19 Investigators","Son, Mary Beth F., Nancy Murray, Kevin Friedman, Cameron C. Young, Margaret M. Newhams, Leora R. Feldstein, Laura L. Loftis, Keiko M. Tarquinio, Aalok R. Singh, Sabrina M. Heidemann, Vijaya L. Soma, Becky J. Riggs, Julie C. Fitzgerald, Michele Kong, Sule Doymaz, John S. Giuliano, Michael A. Keenaghan, Janet R. Hume, Charlotte V. Hobbs, Jennifer E. Schuster, Katharine N. Clouser, Mark W. Hall, Lincoln S. Smith, Steven M. Horwitz, Stephanie P. Schwartz, Katherine Irby, Tamara T. Bradford, Aline B. Maddux, Christopher J. Babbitt, Courtney M. Rowan, Gwenn E. McLaughlin, Phoebe H. Yager, Mia Maamari, Elizabeth H. Mack, Christopher L. Carroll, Vicki L. Montgomery, Natasha B. Halasa, Natalie Z. Cvijanovich, Bria M. Coates, Charles E. Rose, Jane W. Newburger, Manish M. Patel, and Adrienne G. Randolph. ",,2021-06-16,"2022-09-27 - general asset review - Treatment & Care group (to archive)
2022-07 by Amyna, Special Populations Treatment & Care group (said 3 years - in SPORSA went with SP)",,Y,,,Publication,,2025-07,,,,,,,,,,"Son, Mary Beth F., Nancy Murray, Kevin Friedman, Cameron C. Young, Margaret M. Newhams, Leora R. Feldstein, Laura L. Loftis, Keiko M. Tarquinio, Aalok R. Singh, Sabrina M. Heidemann, Vijaya L. Soma, Becky J. Riggs, Julie C. Fitzgerald, Michele Kong, Sule Doymaz, John S. Giuliano, Michael A. Keenaghan, Janet R. Hume, Charlotte V. Hobbs, Jennifer E. Schuster, Katharine N. Clouser, Mark W. Hall, Lincoln S. Smith, Steven M. Horwitz, Stephanie P. Schwartz, Katherine Irby, Tamara T. Bradford, Aline B. Maddux, Christopher J. Babbitt, Courtney M. Rowan, Gwenn E. McLaughlin, Phoebe H. Yager, Mia Maamari, Elizabeth H. Mack, Christopher L. Carroll, Vicki L. Montgomery, Natasha B. Halasa, Natalie Z. Cvijanovich, Bria M. Coates, Charles E. Rose, Jane W. Newburger, Manish M. Patel, and Adrienne G. Randolph. 2021. ""Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes."" New England Journal of Medicine.
","Free online on NEJM.","Background
The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.
Methods
We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2.
Results
A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score–matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score–matched analysis.
Conclusions
Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Funded by the Centers for Disease Control and Prevention.)
",https://www.nejm.org/doi/full/10.1056/NEJMoa2102605,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.nejm.org/doi/full/10.1056/NEJMoa2102605,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Outcomes,Pediatrics,R-Res&Pub,R-SP,SARS-CoV-2,Therapeutics",,Publication,Discover,1,0
1329,https://repository.netecweb.org/items/show/1329,"NETEC COVID-19 Webinar Series (10/16/20)/Online Course: Pediatric Perspectives During a Pandemic","Treatment & Care","In this webinar, we’ll describe the epidemiology of acute COVID-19, including post-infectious manifestations and the unique aspects of caring for children during a pandemic. We will also discuss the features of MIS-C and how to devise a diagnostic and acute management plan and integrate potential post-recovery complications into the development of follow-up plans for a child with MIS-C.
Webinar slides attached.
Get educational credit for this webinar through Courses.netec.org.
",NETEC,,,2020-10-16,"2022-09-27 - general asset review - Treatment & Care group
2022-07 by Amyna, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - skipped - bump to next review",,"Y
Y - D0.1Tx/D0.2Tx Qualtrics # 811, original # 3b",,,"Webinar and Online Course",,2024-04-27,,,,,,,"
",,"CEU online course: https://courses.netec.org/courses/20-web-peds2",,,,,,,,,,,,,,"Friday, October 16, 2020 | 1:00 PM EST",,,,,,,,,,,,,,,,,https://youtu.be/mseYyxUrMk4,"Webinar, watch at link below",,,"2019-nCoV,CEU,CEUs,Children,Clinical Care,Complications,Coronavirus,COVID-19,Online Course,Pandemic,Pediatrics,R-SP,R-T&C,Treatment and Care,Webinar",https://repository.netecweb.org/files/original/840a5b3eb0d83e90f0f487520d270e08.pdf,Webinar,Deploy,1,0
432,https://repository.netecweb.org/items/show/432,"Unique Considerations in the Management of Children with Ebola Virus Disease ","Treatment & Care","NETEC past class slides 2015-2016",NETEC,"Andi L. Shane MD MPH MSc and Ted Cieslak MD
Kari Simonsen MD
Jaime Mukherjee MSN",,2016,"2022-09-27 - general asset review - Treatment & Care group",,,,,,,2025-09-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Children,Ebola,Pediatrics,R-T&C,Treatment and Care,Viral Hemorrhagic Fever",https://repository.netecweb.org/files/original/038ce2ef4b41e365813ddd102d0807b0.pdf,"In Person Course",Discover,1,0
1634,https://repository.netecweb.org/items/show/1634,"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial",Research,"Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3–17 years.","Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu Zhao, Jun Zhao, LiLi Huang, XueZhong Shi, YongLi Yang, GuangXue Xu, WenLing Wang, PeiPei Liu, Meng Ma, YuLing Qiao, SuHua Zhao, JingJing Chai, QinQin Li, Hui Fu, Ying Xu, XiaoTong Zheng, WanShen Guo, and XiaoMing Yang. ",,,2021-09-15,,,,,,Publication,,,,,,,,,,,,"Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu Zhao, Jun Zhao, LiLi Huang, XueZhong Shi, YongLi Yang, GuangXue Xu, WenLing Wang, PeiPei Liu, Meng Ma, YuLing Qiao, SuHua Zhao, JingJing Chai, QinQin Li, Hui Fu, Ying Xu, XiaoTong Zheng, WanShen Guo, and XiaoMing Yang. 2021. ""Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial."" The Lancet Infectious Diseases.
","Free online through Lancet site.","
Background
Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3–17 years.
Methods
A randomised, double-blind, controlled, phase 1/2 trial was done at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan, China. In phases 1 and 2, healthy participants were stratified according to age (3–5 years, 6–12 years, or 13–17 years) and dose group. Individuals with a history of SARS-CoV-2 or SARS-CoV infection were excluded. All participants were randomly assigned, using stratified block randomisation (block size eight), to receive three doses of 2 μg, 4 μg, or 8 μg of vaccine or control (1:1:1:1) 28 days apart. The primary outcome, safety, was analysed in the safety set, which consisted of participants who had received at least one vaccination after being randomly assigned, and had any safety evaluation information. The secondary outcomes were geometric meant titre (GMT) of the neutralising antibody against infectious SARS-CoV-2 and were analysed based on the full analysis set. This study is registered with
www.chictr.org.cn, ChiCTR2000032459, and is ongoing.
Findings
Between Aug 14, 2020, and Sept 24, 2020, 445 participants were screened, and 288 eligible participants were randomly assigned to vaccine (n=216, 24 for each dose level [2/4/8 μg] in each of three age cohorts [3–5, 6–12, and 13–17 years]) or control (n=72, 24 for each age cohort [3–5, 6–12, and 13–17 years]) in phase 1. In phase 2, 810 participants were screened and 720 eligible participants were randomly assigned and allocated to vaccine (n=540, 60 for each dose level [2/4/8 μg] in each of three age cohorts [3–5, 6–12, and 13–17 years]) or control (n=180, 60 for each age cohort [3–5, 6–12, and 13–17 years]). The most common injection site adverse reaction was pain (ten [4%] 251 participants in all vaccination groups of the 3–5 years cohort; 23 [9·1%] of 252 participants in all vaccination groups and one [1·2%] of 84 in the control group of the 6–12 years cohort; 20 [7·9%] of 252 participants in all vaccination groups of the 13–17 years cohort). The most common systematic adverse reaction was fever (32 [12·7%] of 251 participants in all vaccination groups and six [7·1%] of 84 participants in the control group of the 3–5 years cohort; 13 [5·2%] of 252 participants in the vaccination groups and one [1·2%] of 84 in the control group of the 6–12 years cohort; 26 [10·3%] of 252 participants in all vaccination groups and eight [9·5%] of 84 in the control group of the 13–17 years cohort). Adverse reactions were mostly mild to moderate in severity. The neutralising antibody GMT against the SARS-CoV-2 virus ranged from 105·3 to 180·2 in the 3–5 years cohort, 84·1 to 168·6 in the 6–12 years cohort, and 88·0 to 155·7 in the 13–17 years cohort on day 28 after the second vaccination; and ranged from 143·5 to 224·4 in the 3–5 years cohort, 127 to 184·8 in the 6–12 years cohort, and 150·7 to 199 in the 13–17 years cohort on day 28 after the third vaccination.
Interpretation
The inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3–17 years. BBIBP-CorV also elicited robust humoral responses against SARS-CoV-2 infection after two doses. Our findings support the use of a 4 μg dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19.
Funding
National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan.
Translation
For the Chinese translation of the abstract see Supplementary Materials section.
",https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00462-X/fulltext,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00462-X/fulltext,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Pediatrics,R-Res&Pub,Vaccine Study",https://repository.netecweb.org/files/original/e2f0df641ee70a26ff78d6187f9e90e6.png,Publication,Discover,1,0
1288,https://repository.netecweb.org/items/show/1288,"COVID-19 and multisystem inflammatory syndrome in children and adolescents",Research,"As severe acute respiratory syndrome coronavirus 2 continues to spread worldwide, there have been increasing reports from Europe, North America, Asia, and Latin America describing children and adolescents with COVID-19-associated multisystem inflammatory conditions.
A response to this article was published:
","Jiang, Li, Kun Tang, Mike Levin, Omar Irfan, Shaun K. Morris, Karen Wilson, Jonathan D. Klein, and Zulfiqar A. Bhutta.",,,2020-08-17,"2022-07 by Amyna, Special Populations Treatment & Care group",,Y,,,Publication,,2024-07-31,,,,,,,,,,"Jiang, Li, Kun Tang, Mike Levin, Omar Irfan, Shaun K. Morris, Karen Wilson, Jonathan D. Klein, and Zulfiqar A. Bhutta. 2020. ""COVID-19 and multisystem inflammatory syndrome in children and adolescents."" The Lancet Infectious Diseases.
","Free online on Lancet site.","Summary
As severe acute respiratory syndrome coronavirus 2 continues to spread worldwide, there have been increasing reports from Europe, North America, Asia, and Latin America describing children and adolescents with COVID-19-associated multisystem inflammatory conditions. However, the association between multisystem inflammatory syndrome in children and COVID-19 is still unknown. We review the epidemiology, causes, clinical features, and current treatment protocols for multisystem inflammatory syndrome in children and adolescents associated with COVID-19. We also discuss the possible underlying pathophysiological mechanisms for COVID-19-induced inflammatory processes, which can lead to organ damage in paediatric patients who are severely ill. These insights provide evidence for the need to develop a clear case definition and treatment protocol for this new condition and also shed light on future therapeutic interventions and the potential for vaccine development.
Translations
For the French, Chinese, Arabic, Spanish and Russian translations of the abstract see Supplementary Materials section.
",https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30651-4/fulltext,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30651-4/fulltext,,,,"2019-nCoV,Children,Clinical Care,Coronavirus,COVID-19,Neonates,Pediatrics,R-Res&Pub,R-SP,Treatment and Care",,Publication,Discover,1,0
1718,https://repository.netecweb.org/items/show/1718,"Ventilation in Schools and Childcare Programs","Infection Control","How to use CDC building recommendations in your setting",CDC,,,2021-02-26,,,,,,,,2023-10-06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/ventilation.html,,,,"Children,COVID-19,Pediatrics,Public Health,R-SP,School",,Hyperlink,Develop,1,0
1717,https://repository.netecweb.org/items/show/1717,"Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning","Infection Control","On This Page
- Introduction
- Strategies for Everyday Operations
- COVID-19 Community Levels and Associated Prevention Strategies
- Considerations for Prioritizing Strategies
",CDC,,,2022-10-05,"2022-07 by Andi, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - note ""constantly updated""",,,,,,,2024-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-childcare-guidance.html,,,,"Children,COVID-19,Example,Mask,Masks,Pediatrics,Public Health,R-SP",,Hyperlink,Develop,1,0
1276,https://repository.netecweb.org/items/show/1276,"Helping Children Wear Masks","Infection Control","Wearing a mask can be difficult for all of us. How can you teach and help a child to wear a mask? ",NETEC,,,2020-08-06,"2022-07 by Clayton, Special Populations Treatment & Care group",,,,,,,2025-07-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Mask,Masks,Pediatrics,R-SP",https://repository.netecweb.org/files/original/2cc0ae08fcb655ce947e7ac33a7c5749.pdf,Guide,Develop,1,0
1271,https://repository.netecweb.org/items/show/1271,"How to Screen Your Child for COVID-19 Symptoms","Infection Control","As parents, we’re always mindful of how our children are feeling before they go to school. But this year we’ll have to pay more attention than ever to do our part to minimize the spread of germs.
Printable flyer.
See this and related resources:
https://www.strong4life.com/en/landing-pages/parent-resources","Children's Healthcare of Atlanta (CHOA)",,,2020-08-07,"2022-12-07 general asset review - IPC (change to R-SP)",,,,,,,2023-12-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.strong4life.com/~/media/files/Strong4Life/Programs/School-Programs/back-to-school-2020/how-to-screen-your-child-for-covid-19-symptoms-checklist.pdf,,,,"2019-nCoV,Checklist,Children,Coronavirus,COVID-19,R-SP,Screening Tool",,Guide,Develop,1,0
1632,https://repository.netecweb.org/items/show/1632,"Transmission Interrupted Podcast: Kids Coping With COVID-19","Emergency Management","The COVID-19 pandemic continues to affect the pediatric community. With the return to school and the surge in pediatric COVID-19 cases, young children face challenges they’ve never met before, both at school and home. Join host Vanessa Raabe and special guest Abby Hollis, a Certified Child Life Specialist at Children’s Healthcare of Atlanta, as they discuss the challenges facing young children today and highlight various strategies and resources that parents, teachers, and healthcare workers can use to help kids cope with COVID-19 during the pandemic.
Questions or comments for NETEC? Contact us: info@netec.org
Find us on the web: netec.org
Host
Vanessa N. Raabe, MD
Adult and Pediatric Infectious Disease Physician at NYU Grossman School of Medicine
Guest
Abby Hollis
Certified Child Life Specialist at Children’s Healthcare of Atlanta
Resources
Association of Child Life Professionals: https://www.childlife.org
Coronavirus, a Book for Children, written by Elizabeth Jenner, Kate Wilson and Nia Roberts. FREE DOWNLOAD at https://stayhome.candlewick.com
NETEC COVID-19 Novel Coronavirus Resources: https://repository.netecweb.org/exhibits/show/ncov/ncov
NETEC COVID-19 Webinar Series Playlist: https://www.youtube.com/playlist?list=PL5JyGXQ8MP0TZXU2Ldy-jzjLuUNfFX8JZ
NETEC Resource Repository: https://repository.netecweb.org
",NETEC,,,2021-09-29,"2022-07 by Kari, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group (3 yr)",,,,,Podcast,,2026-09-31,,,,,,,"
",,https://netec.org/podcast/,,,,,,,,,,,,,,00:15:21,,,,,,,,,,,,,,,,,https://player.captivate.fm/episode/b310f16d-ef25-4a2f-b139-f472d2b6ca17,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Mental Health,Pediatrics,R-SP",https://repository.netecweb.org/files/original/d8535b5528c22f8f20bc2c253e24a12a.png,Webinar,Develop,1,0
1628,https://repository.netecweb.org/items/show/1628,"PPE, Calculators & Essential Skills","Emergency Management","This page gathers a collection of tools related to PPE, Calculators & Essential Skills for clinicians.","Emergency Medical Services for Children Innovation and Improvement Center (EIIC)",,,2021,"2022-07 by Kari, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group - note ""Constantly updated Excellent resource""",,,,,,,2024-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://emscimprovement.center/education-and-resources/toolkits/pediatric-disaster-preparedness-toolbox/covid-19-coronavirus/domainspreparednesscoronavirus-covid-19ppe/,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Example,Pediatrics,Personal Protective Equipment (PPE),R-SP",https://repository.netecweb.org/files/original/2d10f7950e919d98a260c1fb3bee7fa7.png,Hyperlink,Develop,1,0
1286,https://repository.netecweb.org/items/show/1286,"Children's Reopening Toolkit for Youth Organizations","Emergency Management","As we reopen, children—and those who serve them—need support more than ever. Use the resources in this toolkit as a steppingstone to help protect the kids and staff within your organization.
Find this and related resources: https://www.strong4life.com/en/landing-pages/schools-reopening","Children's Healthcare of Atlanta (CHOA)",,,2020-08,"2022-07 by Nicole, Special Populations Treatment & Care group
2023-12-15 by Clayton Mowrer, Special Populations Treatment & Care group",,,,,,,2024-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.strong4life.com/~/media/files/Strong4Life/Programs/School-Programs/back-to-school-2020/childrens-reopening-toolkit-youth-organizations.pdf,,,,"2019-nCoV,Children,Contingency and crisis capacities,Coronavirus,COVID-19,Emergency Management,Epidemic,Example,Pandemic,Pediatrics,R-EM,R-SP",,Guide,Develop,1,0
1328,https://repository.netecweb.org/items/show/1328,"Como ayudar los niños a usar máscaras","Elementos en Español","Spanish Language version of Helping Children Wear Masks. Wearing a mask can be difficult for all of us. How can you teach and help a child to wear a mask?
Usar una máscara puede ser difícil para todos. ¿Como puedes ensenar y ayudar un niño a usar una máscara?",NETEC,,,2020-09-21,,,,,,,,2024-01-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Español,Mask,Masks,Pediatrics,R-SP,Respiratory Pathogen,Spanish",https://repository.netecweb.org/files/original/89346b06216b2fd95fb4b030ef234c49.pdf,Guide,,1,0
1298,https://repository.netecweb.org/items/show/1298,"Cuidado de pacientes con COVID-19 pediátricos","Elementos en Español","Caring for Pediatric Patients with COVID-19 in Spanish.",NETEC,,,2020-06-29,,,,,,,,2024-01-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2019-nCoV,Children,Coronavirus,COVID-19,Emergency Department,Español,Hospital Rooms,Pediatrics,R-SP,Spanish",https://repository.netecweb.org/files/original/d82467093edfde3c8151f15c8bf2d3fa.pdf,Guide,,1,0